JP2006503109A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503109A5 JP2006503109A5 JP2005500968A JP2005500968A JP2006503109A5 JP 2006503109 A5 JP2006503109 A5 JP 2006503109A5 JP 2005500968 A JP2005500968 A JP 2005500968A JP 2005500968 A JP2005500968 A JP 2005500968A JP 2006503109 A5 JP2006503109 A5 JP 2006503109A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- arsenic trioxide
- composition
- final
- hydrochloric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 28
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 239000008223 sterile water Substances 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 239000000843 powder Substances 0.000 claims 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims 5
- 206010066476 Haematological malignancy Diseases 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41720002P | 2002-10-09 | 2002-10-09 | |
| US60/417,200 | 2002-10-09 | ||
| US48301403P | 2003-06-25 | 2003-06-25 | |
| US60/483,014 | 2003-06-25 | ||
| PCT/CN2003/000843 WO2004032822A2 (en) | 2002-10-09 | 2003-10-08 | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503109A JP2006503109A (ja) | 2006-01-26 |
| JP2006503109A5 true JP2006503109A5 (enExample) | 2006-11-02 |
| JP4786341B2 JP4786341B2 (ja) | 2011-10-05 |
Family
ID=32096185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005500968A Expired - Lifetime JP4786341B2 (ja) | 2002-10-09 | 2003-10-08 | 三酸化ヒ素を含む経口組成物の処方およびその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7521071B2 (enExample) |
| EP (2) | EP3106169B1 (enExample) |
| JP (1) | JP4786341B2 (enExample) |
| CN (1) | CN103340899A (enExample) |
| AU (1) | AU2003271510A1 (enExample) |
| WO (1) | WO2004032822A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044559C (zh) * | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
| US20080166425A1 (en) * | 2002-10-09 | 2008-07-10 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| US20080089949A1 (en) * | 2006-10-13 | 2008-04-17 | Yok-Lam Kwong | Method for treating cancer using oral arsenic trioxide |
| US7521071B2 (en) * | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| US8906422B2 (en) * | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| US8435959B2 (en) | 2004-03-29 | 2013-05-07 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
| US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| US20100009928A1 (en) * | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
| WO2008046299A1 (en) * | 2006-10-11 | 2008-04-24 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| US8795738B2 (en) | 2009-11-12 | 2014-08-05 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| US8834938B2 (en) | 2011-05-18 | 2014-09-16 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| CN103142648B (zh) * | 2011-12-07 | 2015-04-15 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
| ES2641847T3 (es) | 2012-09-20 | 2017-11-14 | Yogesh Narayan BENDALE | Proceso para biosintetizar nanotrióxido de arsénico y su uso en el tratamiento de enfermedades que incluyen el cáncer |
| WO2014151317A1 (en) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Methods for treating cancer |
| SG11201706150QA (en) | 2015-01-29 | 2017-08-30 | Eupharma Pty Ltd | Compositions containing arsenic and their use in methods of treatment |
| US10111836B2 (en) | 2015-02-01 | 2018-10-30 | Orsenix Holdings Bv | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| KR102015858B1 (ko) * | 2015-10-23 | 2019-08-30 | 손영태 | 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물 |
| IL265986B (en) | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof |
| CN111184703B (zh) * | 2018-11-15 | 2023-03-28 | 哈尔滨医大药业股份有限公司 | 三氧化二砷缓释小丸及其制备方法 |
| US11583552B2 (en) | 2021-02-17 | 2023-02-21 | Manoj Maniar | Pharmaceutical formulation of arsenic trioxide |
| EP4455672A1 (en) | 2023-04-26 | 2024-10-30 | Medsenic | Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers |
| WO2025172482A1 (en) | 2024-02-14 | 2025-08-21 | Institut Gustave Roussy | Oral composition of arsenic trioxide for cancer treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875451B2 (en) * | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| ES2395515T3 (es) * | 1997-11-10 | 2013-02-13 | Memorial Sloan Kettering Cancer Center | Trióxido de arsénico para uso en el tratamiento de la leucemia |
| FR2786103A1 (fr) * | 1998-10-30 | 2000-05-26 | Assist Publ Hopitaux De Paris | Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique |
| CN1176665C (zh) * | 2001-02-15 | 2004-11-24 | 暨南大学 | 治疗恶性淋巴瘤的药物及其配制方法 |
| US7521071B2 (en) * | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
-
2003
- 2003-09-23 US US10/669,869 patent/US7521071B2/en not_active Expired - Lifetime
- 2003-10-08 CN CN2013101363192A patent/CN103340899A/zh active Pending
- 2003-10-08 AU AU2003271510A patent/AU2003271510A1/en not_active Abandoned
- 2003-10-08 JP JP2005500968A patent/JP4786341B2/ja not_active Expired - Lifetime
- 2003-10-08 EP EP16167636.6A patent/EP3106169B1/en not_active Expired - Lifetime
- 2003-10-08 EP EP03753241.3A patent/EP1562616B1/en not_active Expired - Lifetime
- 2003-10-08 WO PCT/CN2003/000843 patent/WO2004032822A2/en not_active Ceased